Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
jRCT2080223862Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in B-cell non-Hodgkin lymphoma (B-NHL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Eisai Co., Ltd. Primary endpoint: Overall response rate in follicular lymphoma cohort. Started Apr 2018; status: completed.
02
Drugs
tazemetostat
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2080223862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223862.